Anemia in breast cancer patients reduced by epoetin alfa with no negative impact on s

[News]

In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free (RFS) or overall survival (OS)...

More... (http://www.medicalnewstoday.com/releases/263576.php)